TriangleNCT00952289 · OUTCOME
Maintenance of a ≥ 35% Reduction From Baseline in Spleen Volume Among Patients Initially Randomized to Receive Ruxolitinib
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- proportion of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline Visit and every 12 weeks until the data cut-off date (up to 14 months).
What was measured
The maintenance of ≥ 35% reduction from Baseline in spleen volume was assessed up until the data cutoff date using the Kaplan-Meier method for patients who had at least one measured ≥ 35% reduction, and who either had at least one subsequent measurement or who subsequently dropped out prior to another assessment.
Analysis population: Patients who had at least 1 measurement of ≥ 35% reduction from Baseline in spleen volume at any time during the study and had at least 1 subsequent measurement or withdrew prior to another assessment.
Groups in this outcome
Ruxolitinib
Participants began treatment with ruxolitinib 15 or 20 mg taken orally twice a day based on Baseline platelet count. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily.
| Group | Source count |
|---|---|
| Ruxolitinib | 91 |
Reported measurements
Still Responder by 48 weeks
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ruxolitinib | 0.76 | Not reported | 0.66 | 0.84 | Not reported |
Still Responder by 96 weeks
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ruxolitinib | 0.67 | Not reported | 0.55 | 0.76 | Not reported |
Still Responder by 144 weeks
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ruxolitinib | 0.27 | Not reported | 0.02 | 0.63 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.66
- upper Limit
- 0.84
- value
- 0.76
- title
- Still Responder by 48 weeks
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.55
- upper Limit
- 0.76
- value
- 0.67
- title
- Still Responder by 96 weeks
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.02
- upper Limit
- 0.63
- value
- 0.27
- title
- Still Responder by 144 weeks
- denoms
- counts
- group Id
- OG000
- value
- 91
- units
- Participants
- description
- The maintenance of ≥ 35% reduction from Baseline in spleen volume was assessed up until the data cutoff date using the Kaplan-Meier method for patients who had at least one measured ≥ 35% reduction, and who either had at least one subsequent measurement or who subsequently dropped out prior to another assessment.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants began treatment with ruxolitinib 15 or 20 mg taken orally twice a day based on Baseline platelet count. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily.
- id
- OG000
- title
- Ruxolitinib
- param Type
- NUMBER
- population Description
- Patients who had at least 1 measurement of ≥ 35% reduction from Baseline in spleen volume at any time during the study and had at least 1 subsequent measurement or withdrew prior to another assessment.
- reporting Status
- POSTED
- time Frame
- Baseline Visit and every 12 weeks until the data cut-off date (up to 14 months).
- title
- Maintenance of a ≥ 35% Reduction From Baseline in Spleen Volume Among Patients Initially Randomized to Receive Ruxolitinib
- type
- SECONDARY
- unit Of Measure
- proportion of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice